Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
10 oct. 2022 08h00 HE
|
Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...